Payment overview · 2025
General Payments
$516.21
24 reported records · 14 companies
Healthcare provider profile · identity verified
Robert J Ternes, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WAYNESBORO, PA · NPI 1699703215
Verified facts
What the public records show
CMS Open Payments records show Robert J Ternes, M.D. received $516.21 in general payments during 2025 across 24 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 24.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $128.45 | 24.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $74.21 | 14.4% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $58.73 | 11.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.29 | 6.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.02 | 6.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.77 | 5.8% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $29.28 | 5.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.37 | 4.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.20 | 4.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.04 | 4.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.13 | 3.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.75 | 3.2% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $14.23 | 2.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.74 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $516.21 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $142.19 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $58.73 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $56.51 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $45.88 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $42.77 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $32.02 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $24.37 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.20 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.04 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.70 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 149 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 40 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
58 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | 14 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
149 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
149 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 413 | 128 |
| Lisinopril | Lisinopril | 330 | 109 |
| Omeprazole | Omeprazole | 313 | 95 |
| Amlodipine Besylate | Amlodipine Besylate | 295 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 266 | 86 |
| Alprazolam | Alprazolam | 243 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 218 | 62 |
| Simvastatin | Simvastatin | 193 | 57 |
| Metformin Hcl | Metformin Hcl | 188 | 61 |
| Ezetimibe | Ezetimibe | 163 | 59 |
| Buspirone Hcl | Buspirone Hcl | 159 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 156 | 49 |
| Losartan Potassium | Losartan Potassium | 153 | 47 |
| Eliquis | Apixaban | 149 | 36 |
| Furosemide | Furosemide | 141 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 140 | 43 |
| Gabapentin | Gabapentin | 138 | 41 |
| Montelukast Sodium | Montelukast Sodium | 123 | 41 |
| Potassium Chloride | Potassium Chloride | 123 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 115 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 113 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 112 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 96 | 34 |
| Lorazepam | Lorazepam | 95 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 93 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 89 | 37 |
| Glipizide Er | Glipizide | 87 | 20 |
| Prednisone | Prednisone | 79 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 78 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 15 |
| Azithromycin | Azithromycin | 77 | 59 |
| Carvedilol | Carvedilol | 76 | 18 |
| Tramadol Hcl | Tramadol Hcl | 73 | 31 |
| Meloxicam | Meloxicam | 72 | 23 |
| Dicyclomine Hcl | Dicyclomine Hcl | 70 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 19 |
| Ramipril | Ramipril | 61 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 60 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 19 |
| Synthroid | Levothyroxine Sodium | 58 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 15 |
| Meclizine Hcl | Meclizine Hcl | 48 | 26 |
| Allopurinol | Allopurinol | 46 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 33 |
| Oxycodone Hcl | Oxycodone Hcl | 42 | suppressed |
| Famotidine | Famotidine | 41 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 41 | suppressed |
| Fenofibrate | Fenofibrate | 40 | 14 |
| Jardiance | Empagliflozin | 40 | 14 |
| Spironolactone | Spironolactone | 40 | suppressed |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 38 | 13 |
| Clindamycin Hcl | Clindamycin Hcl | 37 | 29 |
| Metformin Hcl Er | Metformin Hcl | 37 | 12 |
| Gemfibrozil | Gemfibrozil | 35 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | 11 |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Valsartan | Valsartan | 32 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Atenolol | Atenolol | 30 | 11 |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Creon | Lipase/Protease/Amylase | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | 11 |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 24 | suppressed |
| Nystatin | Nystatin | 24 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 23 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 14 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Ozempic | Semaglutide | 18 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Oxazepam | Oxazepam | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Felodipine Er | Felodipine | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 14 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Levetiracetam Er | Levetiracetam | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $516.21 · 24 records | E.R. Squibb & Sons, L.L.C. | AIRSUPRA, CeQur Simplicity, Cologuard Collection Kit, ELIQUIS, FARXIGA, JARDIANCE, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, XIFAXAN, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error